Mouse Anti-Bovine CD6 Hybridoma [DD49]

Introduction: ALCAM, activated leukocyte cell adhesion molecule, is connected to the progression of certain solid tumours and has been shown to be a prominent feature for tumours that subsequently developed bone metastasis. The present stud), investigated the biological influence of ALCAM on breast cancer cells in connection with bone biological environment. Materials and Methods: Suitable breast cancer cells were transfected with either the ALCAM expression construct or anti-ALCAM trans gene, to create sublines that had differential expression of ALCAM. The growth, migration and invasion of the cells were evaluated in the presence or absence of matrix proteins prepared from human bones. Results: ZR-751(Delta ALCAM) (ALCAM knockdown) and MDA-MB-231(ALCAMexp) (overexpressing ALCAM) were constructed. mDA MB-231(ALCAMexp) cells showed a slower rate of growth compared with control cells. However, in the presence of bone matrix proteins, MDA MB-231(ALCAMexp) showed a significantly reduced rate of growth, p<0.01 vs. control cells. In contrast, ZR-751(Delta ALCAM) cells grew faster compared with control cells. MDA MB-231(ALCAMexp) displayed a significantly reduced (p=0.012) and ZR-751(Delta ALCAM) cells significantly increased invasiveness (p=0.02) vs. their respective controls cells. In an ECIS-based cell migration assay, MDA-MB-231(ALCAMexp) cells showed marked reduction in migration. Inclusion of bone matrix proteins therefore further reduced the migration speed of MDA MB-231(ALCAMexp) cells. Conclusion: Loss of ALCAM in breast cancer cells facilitates the invasive behaviour of breast cancer and high levels of ALCAM in the cells have a suppressive role in the aggressive nature of breast cancer cells.

Objective: CD6 is emerging as a new target for treating many pathological conditions in which T cells are integrally involved, but even the latest data from studies of CD6 gene engineered mice were still contradictory. To address this issue, we studied experimental autoimmune uveitis (EAU), a model of auto immune uveitis, in wild-type (WT) and CD6 knockout (1(0) mice. Methods: After EAU induction in WT and CD6 KO mice, we evaluated ocular inflammation and compared retinal antigen-specific T-cell responses using scanning laser ophthalmoscopy, spectral-domain optical coherence tomography, histopathology, and T cell recall assays. Uveitogenic T cells from WT and CD6 KO mice were adoptively transferred into WT naive mice to confirm the impact of CD6 on T cells. In addition, we immunized CD6 KO mice with recombinant CD6 protein to develop mouse anti-mouse CD6 monoclonal antibodies (mAbs) in which functional antibodies exhibiting cross-reactivity with human CD6 were screened and identified for treatment studies. Results: In CD6 KO mice with EAU, we found significantly decreased retinal inflammation and reduced autoreactive T-cell responses, and confirmed the impaired uveitogenic capacity of T cells from these mice in an adoptive transfer experiment. Notably, one of these cross-reactive mAbs significantly ameliorated retinal inflammation in EAU induced by the adoptive transfer of uveitogenic T cells. Conclusions: Together, these data strongly suggest that CD6 plays a previously unknown, but pivotal role in autoimmune uveitis, and may be a promising new treatment target for this blinding disease. In addition, the newly developed mouse anti-mouse/human CD6 mAbs could be valuable tools for testing CD6-targeted therapies in other mouse models of human diseases. (C) 2018 Elsevier Ltd. All rights reserved.